09:55 EDT Vaccinex trading resumes
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCNX:
- Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
- Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab
- Vaccinex files to sell 490,509 shares of common stock for holders
- Vaccinex Completes Key Study Phase for Alzheimer’s Drug
- Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease